TL;DR
Our immune system relies on the RIG-I-MAVS pathway to detect viral RNA and mount an antiviral response. This pathway is triggered by MAVS protein aggregation, but how this aggregation is controlled is unclear. This study identifies WDR77 as a key regulator that binds to MAVS, preventing its aggregation and thus dampening the antiviral response, which is crucial for preventing harmful inflammation.
What Problem Does This Paper Address?
The innate immune system is our first line of defense against pathogens. A critical component of this defense is the RIG-I-MAVS signaling pathway, which detects viral RNA and initiates an antiviral response. This response is activated when the adaptor protein MAVS forms "prion-like" aggregates. While this aggregation is essential for signaling, its precise regulation is not fully understood. Dysregulation of MAVS aggregation can lead to excessive inflammation and autoimmune diseases. Therefore, identifying the mechanisms that control MAVS aggregation is crucial for understanding and potentially treating inflammatory and autoimmune conditions. This paper aims to uncover these regulatory mechanisms by identifying proteins that interact with MAVS and influence its aggregation.
Methods
The researchers employed a multi-pronged approach:
- Affinity Purification and Mass Spectrometry: They used Flag-tagged MAVS to pull down interacting proteins from cell lysates, followed by silver staining and mass spectrometry to identify potential MAVS-binding partners.
- Co-immunoprecipitation (Co-IP) and Immunoblotting: These techniques were used to confirm direct protein-protein interactions between MAVS and candidate proteins (like WDR77 and PRMT5) and to assess protein levels.
- Luciferase Reporter Assays: These assays were used to measure the transcriptional activity of the IFNB1 promoter, a key output of the RIG-I-MAVS pathway, to assess the impact of WDR77 on antiviral signaling.
- Quantitative PCR (qPCR) and ELISA: These methods were used to quantify the expression of antiviral genes (like IFNB1) and the secretion of IFN-β protein, respectively.
- CRISPR/Cas9 and shRNA Knockout/Knockdown: These genetic tools were used to generate cell lines and mice deficient in WDR77 to study its function in the absence of the protein.
- Immunofluorescence Microscopy: This technique was used to visualize the cellular localization of WDR77 and MAVS and to assess their co-localization.
- Semi-denaturing Detergent Agarose Gel Electrophoresis (SDD-AGE): This method was used to detect and quantify MAVS aggregation.
- Native PAGE: Used to detect IRF3 dimerization, another indicator of RIG-I-MAVS pathway activation.
- In vitro Reconstitution Assays: Using subcellular fractions (S5 and P5), researchers reconstituted the signaling pathway in vitro to pinpoint the role of WDR77 in MAVS aggregation.
- Electron Microscopy: Used to visualize the formation of MAVS filaments in vitro.
- Mouse Models: Myeloid-specific Wdr77-deficient mice were generated to study the in vivo role of WDR77 in antiviral immunity.
- Viral Infection Models: Various viruses (Sendai virus, VSV, poly(I:C), HSV-1, IAV) were used to stimulate the RIG-I-MAVS pathway and assess antiviral responses.
Datasets
Not discussed in the paper.
Key Insights and Ideas
- WDR77 as a Novel Regulator: The study identifies WDR77 as a previously unrecognized negative regulator of the RIG-I-MAVS pathway. This is significant because it adds a new layer of control to a critical immune signaling cascade.
- Direct Interaction with MAVS: WDR77 doesn't just indirectly influence MAVS; it directly binds to the proline-rich region of MAVS. This direct interaction is key to its inhibitory function.
- Inhibition of Prion-like Aggregation: The core mechanism of WDR77's action is preventing the formation of MAVS prion-like aggregates. This is a crucial insight into how the innate immune response is kept in check.
- Specificity for RNA Virus Sensing: WDR77's inhibitory effect is primarily observed in response to RNA viruses, suggesting a specific role in the RIG-I-MAVS pathway, rather than general immune suppression.
- In Vivo Relevance: The findings in cell lines are validated in mouse models, showing that WDR77 deficiency leads to enhanced antiviral responses and increased resistance to RNA virus infections.
Key Results
- WDR77 was identified as a MAVS-associated protein through affinity purification and mass spectrometry.
- WDR77 directly binds to the proline-rich region of MAVS via its WD2-WD3-WD4 domains.
- WDR77 inhibits the formation of MAVS prion-like aggregates both in vitro and in vivo.
- WDR77 deficiency in cells and mice leads to potentiated IFNB1 induction and enhanced antiviral gene expression upon stimulation with negative-strand RNA viruses.
- Myeloid-specific Wdr77-deficient mice exhibit increased resistance to RNA virus infection.
- WDR77's inhibitory effect is specific to the RIG-I-MAVS pathway and does not significantly impact DNA-sensing pathways (like CGAS-STING).
Limitations and Future Work
- Structural Basis: While the interaction domains are identified (WD2-WD3-WD4 of WDR77 and proline-rich region of MAVS), the precise atomic-level structural basis of this interaction is not yet elucidated. Future work could involve structural studies (e.g., cryo-EM) to provide a detailed molecular understanding.
- Post-translational Modifications: The study notes that WDR77's role in regulating MAVS aggregation is independent of MAVS ubiquitination. However, the potential involvement of other post-translational modifications (PTMs) on MAVS or WDR77 in this interaction remains to be explored.
- Clinical Relevance in Cancer: The authors mention WDR77's known involvement in various cancers and suggest that its role in inflammation might contribute to cancer development. Further research could investigate the direct link between WDR77 dysfunction, inflammation, and cancer progression.
- Other Regulators: The study acknowledges that other regulators might also influence MAVS aggregation and that exploring these connections could be a valuable future direction.
Summary updated